Benzoyl peroxide is a Small Molecule owned by Sol-Gel Technologies, and is involved in 4 clinical trials, which were completed.

Benzoyl peroxide is a encapsulated benzoyl peroxide (E-BPO). Benzoyl peroxide has a keratolytic and desquamative effect which may also contribute to its efficacy. Benzoyl peroxide gets absorbs by the skin where it is converted to benzoic acid. The active ingredient migrates through the pores of the microcapsules while the barrier improves tolerability of the active ingredient.

The revenue for Benzoyl peroxide is expected to reach a total of $578m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Benzoyl peroxide NPV Report.

Benzoyl peroxide is currently owned by Sol-Gel Technologies.

Benzoyl peroxide Overview

Benzoyl peroxide (Epsolay) is a peroxide with antibacterial, irritant, keratolytic, comedolytic, and anti-inflammatory activity developed based on Sol-Gel drug delivery technology. It is formuaated as cream for topical application. Epsolay for the treatment of inflammatory lesions of rosacea in adults 18 years of age and older. 

Sol-Gel Technologies Overview

Sol-Gel Technologies (Sol-Gel) is a dermatology company that carries out the identification, development and commercialization of investigational and generic topical drug products for the treatment of skin diseases. The company provides products under the brand name EPSOLAY for the treatment of inflammatory lesions of rosacea in adults and TWYNEO for the treatment of acne vulgaris. It also offers SGT-210, SGT-310 and SGT-510 drug candidates to treat plaque psoriasis and other dermatologic indications. Sol-Gel utilizes silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs. It operates in the US and Israel. Sol-Gel is headquartered in Ness Ziona, Israel.

The company reported revenues of (US Dollars) US$31.3 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$8.8 million in FY2020. The operating profit of the company was US$3 million in FY2021, compared to an operating loss of US$30.2 million in FY2020. The net profit of the company was US$3.2 million in FY2021, compared to a net loss of US$29.3 million in FY2020. The company reported revenues of US$0.3 million for the third quarter ended September 2022, a decrease of 92.6% over the previous quarter.

Quick View – Benzoyl peroxide

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Benzoyl peroxide
Administration Pathway
  • Topical
Therapeutic Areas
  • Dermatology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.